Catamaran Bio gathers $42m

Cambridge, Massachusetts-based Catamaran Bio, Inc, a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer, has raised $42 million in financing.

23 November 2020•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles